Adjuvant endocrine therapy for perimenopausal women with early breast cancer

Olaf Ortmann, Tanja Cufer, J. Michael Dixon, Nicolai Maass, Paolo Marchetti, Olivia Pagani, Paolo Pronzato, Vladimir Semiglazov, Jean Philippe Spano, Eduard Vrdoljak, Hans Wildiers

Research output: Contribution to journalArticle

Abstract

Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.

Original languageEnglish
Pages (from-to)2-7
Number of pages6
JournalBreast
Volume18
Issue number1
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Aromatase Inhibitors
Breast Neoplasms
Tamoxifen
Croatia
Therapeutics
Adjuvant Chemotherapy
Gonadotropin-Releasing Hormone
Estrogens
Hormones
Neoplasms

Keywords

  • Adjuvant
  • Breast carcinoma
  • Endocrine therapy
  • Ovarian function suppression
  • Perimenopausal

ASJC Scopus subject areas

  • Surgery

Cite this

Ortmann, O., Cufer, T., Dixon, J. M., Maass, N., Marchetti, P., Pagani, O., ... Wildiers, H. (2009). Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast, 18(1), 2-7. https://doi.org/10.1016/j.breast.2008.10.002

Adjuvant endocrine therapy for perimenopausal women with early breast cancer. / Ortmann, Olaf; Cufer, Tanja; Dixon, J. Michael; Maass, Nicolai; Marchetti, Paolo; Pagani, Olivia; Pronzato, Paolo; Semiglazov, Vladimir; Spano, Jean Philippe; Vrdoljak, Eduard; Wildiers, Hans.

In: Breast, Vol. 18, No. 1, 02.2009, p. 2-7.

Research output: Contribution to journalArticle

Ortmann, O, Cufer, T, Dixon, JM, Maass, N, Marchetti, P, Pagani, O, Pronzato, P, Semiglazov, V, Spano, JP, Vrdoljak, E & Wildiers, H 2009, 'Adjuvant endocrine therapy for perimenopausal women with early breast cancer', Breast, vol. 18, no. 1, pp. 2-7. https://doi.org/10.1016/j.breast.2008.10.002
Ortmann O, Cufer T, Dixon JM, Maass N, Marchetti P, Pagani O et al. Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast. 2009 Feb;18(1):2-7. https://doi.org/10.1016/j.breast.2008.10.002
Ortmann, Olaf ; Cufer, Tanja ; Dixon, J. Michael ; Maass, Nicolai ; Marchetti, Paolo ; Pagani, Olivia ; Pronzato, Paolo ; Semiglazov, Vladimir ; Spano, Jean Philippe ; Vrdoljak, Eduard ; Wildiers, Hans. / Adjuvant endocrine therapy for perimenopausal women with early breast cancer. In: Breast. 2009 ; Vol. 18, No. 1. pp. 2-7.
@article{5fb3a7456d544dcc8beeccbf1951db70,
title = "Adjuvant endocrine therapy for perimenopausal women with early breast cancer",
abstract = "Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.",
keywords = "Adjuvant, Breast carcinoma, Endocrine therapy, Ovarian function suppression, Perimenopausal",
author = "Olaf Ortmann and Tanja Cufer and Dixon, {J. Michael} and Nicolai Maass and Paolo Marchetti and Olivia Pagani and Paolo Pronzato and Vladimir Semiglazov and Spano, {Jean Philippe} and Eduard Vrdoljak and Hans Wildiers",
year = "2009",
month = "2",
doi = "10.1016/j.breast.2008.10.002",
language = "English",
volume = "18",
pages = "2--7",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Adjuvant endocrine therapy for perimenopausal women with early breast cancer

AU - Ortmann, Olaf

AU - Cufer, Tanja

AU - Dixon, J. Michael

AU - Maass, Nicolai

AU - Marchetti, Paolo

AU - Pagani, Olivia

AU - Pronzato, Paolo

AU - Semiglazov, Vladimir

AU - Spano, Jean Philippe

AU - Vrdoljak, Eduard

AU - Wildiers, Hans

PY - 2009/2

Y1 - 2009/2

N2 - Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.

AB - Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen. However, AIs should not be used in premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion.

KW - Adjuvant

KW - Breast carcinoma

KW - Endocrine therapy

KW - Ovarian function suppression

KW - Perimenopausal

UR - http://www.scopus.com/inward/record.url?scp=59849103338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849103338&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2008.10.002

DO - 10.1016/j.breast.2008.10.002

M3 - Article

C2 - 19036588

AN - SCOPUS:59849103338

VL - 18

SP - 2

EP - 7

JO - Breast

JF - Breast

SN - 0960-9776

IS - 1

ER -